ARB 1 6
Alternative Names: ARB-1-6Latest Information Update: 24 Jun 2024
At a glance
- Originator ProteinQure
- Class Antineoplastics; Auristatins; Peptide drug conjugates
- Mechanism of Action Mitosis inhibitors; Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Triple negative breast cancer
Most Recent Events
- 05 Apr 2024 Pharmacodynamics and adverse events data from a preclinical study in Triple-negative breast cancer presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
- 26 Mar 2024 Protein drug conjugate is available for licensing as of 26 Mar 2024. https://www.proteinqure.com/partnering.html (ProteinQure website, March 2024)
- 26 Mar 2024 Pharmacodynamics data from preclinical trial in Triple-negative breast cancer released by ProteinQure, before March 2024